var data={"title":"Arginine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Arginine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5665?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=arginine-drug-information\" class=\"drug drug_general\">see &quot;Arginine: Drug information&quot;</a> and <a href=\"topic.htm?path=arginine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Arginine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136608\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>R-Gene 10</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056560\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent, Growth Hormone Function</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Metabolic Alkalosis Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Urea Cycle Disorder (UCD) Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432602\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders):</b> Limited data available: <b>Note:</b> Administered concomitantly with sodium benzoate and sodium phenylacetate. Dosage based on specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. Do not repeat loading dose unless severe disorder or receiving dialysis; if used, minimum 6 hour interval between loading doses (Summar 2001). <b>Note: Dosing based on arginine hydrochloride product.   </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, Citrullinemia) deficiency:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (Batshaw 2001; NORD 2012; Summar 2001; UCD Conference group 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> IV: Loading dose: 200 mg/kg followed by a continuous IV infusion of 200 mg/kg/day (Batshaw 2001; NORD 2012; Summar 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Comatose patients: IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 250 mg/kg/day (UCD Conference group 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Noncomatose patients: IV: Loading dose: 200 mg/kg followed by a continuous IV infusion of 200 mg/kg/day (Batshaw 2001; NORD 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Unconfirmed/pending diagnosis:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (NORD 2012; Summar 2001). If ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA-directed dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency: IV: Loading dose: 12 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 12 g/<b>m<sup>2</sup></b>/day (Batshaw 2001; Brusilow 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) deficiency: IV: Loading dose: 4 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 4 g/<b>m<sup>2</sup></b>/day (Batshaw 2001; Brusilow 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urea cycle disorders, chronic therapy:</b> Limited data available: <b>Note:</b> Dose should be individualized based on patient response; doses may need to be increased by ~50% as part of a sick-day routine (Berry 2001). <b>Note: Dosing based on arginine-free base powder product:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency</i> (Batshaw 2001; Berry 2001;  Brusilow 1996; NORD 2012; Summar 2001): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Oral: 400 to 700 mg/kg/day in 3 to 4 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: Oral:  8.8 to 15.4 g/m<sup>2</sup>/day in 3 to 4 divided doses  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> <b> Note:</b> Citrulline may be preferred for some patients (Batshaw, 2001; Brusilow 1996; NORD 2012):  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Oral:  170 mg/kg/day in 3 to 4 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: Oral:  3.8 g/m<sup>2</sup>/day in 3 to 4 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Necrotizing enterocolitis (NEC), prevention:</b> Limited data available: Oral, IV: 261 mg/kg/day added to enteral or parenteral nutrition beginning on day of life 2 to 5 and continued for 28 consecutive days. Dosing based on a single-center, prospective, double-blind, randomized, placebo-controlled trial of neonates (Treatment group: n=75, GA: &lt;32 weeks; birth weight: &lt;1,250 g) in Canada. Arginine supplementation decreased the NEC incidence when compared to placebo (6.7% vs 27%) (Amin 2002; Shah 2007). <b>Note:</b> The only commercial product available in the US is arginine HCl injection and it is not known whether the hydrochloride salt was used in the Canadian study. Increased administration of HCl in this patient population could result in hyperchloremic metabolic acidosis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056554\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=arginine-drug-information\" class=\"drug drug_general\">see &quot;Arginine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pituitary function test: Note: Dosing based on arginine hydrochloride product:</b> Infants, Children, and Adolescents: IV: 0.5 <b>g</b>/kg over 30 minutes; maximum dose: 30 <b>g</b> dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic alkalosis:</b> Limited data available: Infants, Children, and Adolescents: IV: <b>Note:</b> Arginine hydrochloride is an alternative treatment for uncompensated metabolic alkalosis after sodium chloride and potassium chloride supplementation have been optimized; it should not be used as initial therapy for chloride supplementation. Each 1 g of arginine hydrochloride provides 4.75 mEq chloride. <b>Note: Dosing based on arginine hydrochloride product.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Arginine hydrochloride dose (mEq) = 0.5 x weight (kg) x [HCO<sub>3</sub><sup>-</sup> - 24] where HCO<sub>3</sub><sup>-</sup> = the patient's serum bicarbonate concentration in mEq/L (Martin 1982); give <sup>1</sup>/<sub>2</sub> to <sup>2</sup>/<sub>3</sub> of calculated dose and reevaluate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">To correct hypochloremia: Arginine hydrochloride dose (mEq) = 0.2 x weight (kg) x [103 - Cl<sup>-</sup>] where Cl<sup>-</sup> = the patient's serum chloride concentration in mEq/L (Martin 1982); give <sup>1</sup>/<sub>2</sub> to <sup>2</sup>/<sub>3</sub> of calculated dose and reevaluate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Administered concomitantly with sodium benzoate and sodium phenylacetate. Dosage based on specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. If patient already receiving arginine therapy, consider either a reduction in the loading dose or possible elimination (Batshaw 2001); if a loading dose is used, it should not be repeated (NORD 2012). <b>Note: Dosing based on arginine hydrochloride product.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (Batshaw 2001; NORD 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase  (NAGS) deficiency:</i> IV: Loading dose: 200 mg/kg followed by a continuous IV infusion of 200 mg/kg/day (Batshaw 2001; NORD 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Unconfirmed/pending diagnosis:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (NORD 2012). If ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> IV: Loading dose: 12 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 12 g/<b>m<sup>2</sup></b>/day (Batshaw 2001; Brusilow 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) disorder:</i> IV: Loading dose: 4 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 4 g/<b>m<sup>2</sup></b>/day (Batshaw 2001; Brusilow 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urea cycle disorders, chronic therapy:</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Dose should be individualized based on patient response; doses may need to be increased by ~50% as part of a sick-day routine (Berry 2001): <b>Note: Dosing based on arginine-free base powder product: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency</i> (Batshaw 2001; Berry 2001; Brusilow 1996; NORD 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Oral:  400 to 700 mg/kg/day in 3 to 4 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-directed dosing: Oral:  8.8 to 15.4 g/m<sup>2</sup>/day in 3 to 4 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase  (NAGS) deficiency:</i> <b>Note:</b> Citrulline may be preferred for some patients (Batshaw, 2001; Brusilow 1996; NORD 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Oral:  170 mg/kg/day in 3 to 4 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-directed dosing: Oral:  3.8 g/m<sup>2</sup>/day in 3 to 4 divided doses  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Pituitary function test:</b> <b>Note: Dosing based on arginine hydrochloride product: </b> IV: 30 g over 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution; use may lead to life-threatening hyperkalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution; use may lead to life-threatening hyperkalemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136592\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">R-Gene 10: 10% (300 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136578\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27747245\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=arginine-drug-information\" class=\"drug drug_general\">see &quot;Arginine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">R-Gene 10 contains chloride 47.5 mEq per 100 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056564\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Arginine hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pituitary function test: Administer undiluted over 30 minutes. For doses &lt;30 g (&lt;300 mL), the manufacturer recommends transferring the dose to a separate container prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hyperammonemia, acute (urea cycle disorders): May administer in combination with sodium benzoate and sodium phenylacetate injection; central line preferred. Administer loading dose over 90 minutes (UCD conference group 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral, powder: Arginine-free base: Take with meals and space doses evenly throughout the day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136607\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F). Do not use if frozen. Once the vial has been punctured, may store for up to 4 hours at 25&deg;C (77&deg;F)  (including infusion time) or 24 hours at (2&deg;C to 8&deg;C).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056563\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Diagnostic agent in pituitary function test (stimulant for the release of growth hormone) (FDA approved in pediatric patients [age not specified] and adults); has also been used for management of severe, uncompensated, metabolic alkalosis (pH &ge;7.55) <b>after</b> optimizing therapy with sodium or potassium chloride supplements treatment; prevention  of necrotizing enterocolitis in neonates; and for treatment/prevention of hyperammonemia associated with urea cycle disorders </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7905819\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Food and Drug Administration (FDA) has identified several cases of fatal arginine overdose in children and has recommended that healthcare professionals always recheck dosing calculations prior to administration of arginine. Doses used in children should not exceed usual adult doses.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136626\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing (with rapid IV infusion), venous irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, numbness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, burning sensation of skin (due to extravasation), cerebral edema, hematuria, hyperkalemia, hypersensitivity reaction, injection site reaction, lethargy, loss of consciousness, oral paresthesia, skin necrosis (due to extravasation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136597\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to arginine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136582\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Irritant with vesicant-like properties. Due to the hypertonicity of the IV solution, administer via IV infusion only with a patent catheter placed within a patent vein. Extravasation has resulted in burn-like reactions and skin necrosis requiring surgical intervention. Excessive rates of infusion (eg, &lt;30 minutes) may result in local irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe reactions, including anaphylaxis, have been reported; if hypersensitivity occurs, discontinue and institute supportive treatment measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-related reactions: Excessive rates of infusion (eg, &lt;30 minutes) may result in flushing, nausea, or vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Use with caution in patients with electrolyte imbalance due to chloride content of product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Arginine metabolism results in excretion of nitrogen-containing products. Use with caution in patients with renal impairment; decreased excretion may result in an increased amino acid or nitrogen burden.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Fatal overdose of arginine in pediatric patients has been reported. Exercise extreme caution when infusing arginine. Overdosage of arginine in children can also result in hyperchloremic metabolic acidosis or cerebral edema.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819766\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates, infants, and children overdosage has resulted in hyperchloremic metabolic acidosis, cerebral edema, or possibly death; each 1 mEq chloride delivers 1 mEq hydrogen; monitor acid base balance closely, particularly in neonates. Arginine hydrochloride is metabolized to nitrogen-containing products for excretion; the temporary effect of a high nitrogen load on the kidneys should be evaluated. Accumulation of excess arginine may result in an overproduction of nitric oxide, leading to vasodilation and hypotension (Summar 2001). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oral  products available in the US are often marketed as dietary supplements. When using these products, patients should take care to ensure that they are receiving pharmaceutical grade supplements of L-arginine and verify the formulation (free base vs arginine HCl). The National Urea Cycle Disorders Foundation cautions against using oral dietary supplements of arginine HCL (National Urea Cycles Disorder Foundation). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298769\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136586\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12797&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136600\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal studies; however, the manufacturer does not recommend use of arginine during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056559\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Acid-base status (arterial or capillary blood gases), serum electrolytes, BUN, glucose, plasma growth hormone concentrations (when evaluating growth hormone reserve), plasma ammonia and amino acids (when treating urea cycle disorders), infusion site </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056562\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pituitary function test: If intact pituitary function, human growth hormone levels should rise after arginine administration to 10-30 ng/mL (control range: 0-6 ng/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea cycle disorders:  Goal arginine: 50 to 200 &mu;mol/L (Leonard  2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136581\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates pituitary release of growth hormone and prolactin through origins in the hypothalamus; patients with impaired pituitary function have lower or no increase in plasma concentrations of growth hormone after administration of arginine. In patients with urea cycle disorders, the formation of arginine is prohibited; therefore, exogenous administration of arginine is required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136596\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~33 L/kg following a 30 g IV dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively metabolized in the liver and intestines (Cynober 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: ~68% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life, elimination: 42 &plusmn; 2 minutes following a 30 g IV dose; exhibits nonlinear, dose-dependent elimination (Tangphao 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: ~2 hours; IV: 22 to 30 minutes (Bode-Boger 1998; Tangphao 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (16% during the first 90 minutes; biphasic elimination) (Tangphao 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056568\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">When treating urea cycle disorders, sodium bicarbonate use may be necessary to neutralize the acidifying effects of arginine HCl (UCD conference group 2001).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Equivalents (Haeberle 2012):</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">100 mg arginine free base = 0.574 mmols</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">100 mg arginine HCL = 0.475 mmol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322999\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (R-Gene 10 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (300 mL): $44.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038532\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arginina (PL);</li>\n      <li>Rocmaline (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adrogu&eacute; HJ and Madias NE, &quot;Management of Life-Threatening Acid-Base Disorders. Second of Two Parts,&quot; <i>N Engl J Med</i>, 1998, 338(2):107-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/9420343/pubmed\" target=\"_blank\" id=\"9420343\">9420343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amin HJ, Zamora SA, McMillan DD, et al, &quot;Arginine Supplementation Prevents Necrotizing Enterocolitis in the Premature Infant,&quot; <i>J Pediatr</i>, 2002, 140(4):425-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/12006956/pubmed\" target=\"_blank\" id=\"12006956\">12006956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ammonul (arginine) [prescribing information]. Baltimore, MD: Cangene bioPharma; July 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):S46-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/11148549/pubmed\" target=\"_blank\" id=\"11148549\">11148549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berry GT, Steiner RD. Long-term management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S56-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/11148550 /pubmed\" target=\"_blank\" id=\"11148550 \">11148550 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bode-B&ouml;ger SM, B&ouml;ger RH, Galland A, et al, &quot;L-Arginine-Induced Vasodilation in Healthy Humans: Pharmacokinetic-Pharmacodynamic Relationship,&quot; <i>Br J Clin Pharmacol</i>, 1998, 46(5):489-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/9833603/pubmed\" target=\"_blank\" id=\"9833603\">9833603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127-170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/8794176 /pubmed\" target=\"_blank\" id=\"8794176 \">8794176 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bushinsky DA and Gennari FJ, &ldquo;Life-Threatening Hyperkalemia Induced by Arginine,&rdquo; <i>Ann Intern Med</i>, 1978, 89(5 Pt 1):632-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/717931 /pubmed\" target=\"_blank\" id=\"717931 \">717931 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    H&auml;berle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. <i>Orphanet J Rare Dis</i>. 2012;7:32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/22642880 /pubmed\" target=\"_blank\" id=\"22642880 \">22642880 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard JV, Morris AA. Urea cycle disorders. <i>Semin Neonatol</i>. 2002 ;7(1):27-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/12069536 /pubmed\" target=\"_blank\" id=\"12069536 \">12069536 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin WJ and Matzke GR, &quot;Treating Severe Metabolic Alkalosis,&quot; <i>Clin Pharm</i>, 1982, 1(1):42-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/6764161/pubmed\" target=\"_blank\" id=\"6764161\">6764161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Organization for Rare Disorders. (NORD). <i>The Physician's Guide to Urea Cycle Disorders</i>. Danbury, CT: National Organization for Rare Disorders; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Urea Cycle Disorders Foundation. Available at http://www.nucdf.org/medical_information.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    R-Gene (arginine hydrochloride) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; January 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah P and Shah V, &quot;Arginine Supplementation for Prevention of Necrotising Enterocolitis in Preterm Infants,&quot; <i>Cochrane Database Syst Rev</i>, 2007, (3):CD004339.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/17636753/pubmed\" target=\"_blank\" id=\"17636753\">17636753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Summar M, &ldquo;Current Strategies for the Management of Neonatal Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):S30-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/11148547/pubmed\" target=\"_blank\" id=\"11148547\">11148547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-pediatric-drug-information/abstract-text/11148543 /pubmed\" target=\"_blank\" id=\"11148543 \">11148543 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12797 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F136608\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056560\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11432602\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056554\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136592\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F136578\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27747245\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056564\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F136607\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056563\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7905819\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136626\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136597\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136582\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819766\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298769\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136586\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136600\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056559\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1056562\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136581\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F136596\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1056568\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322999\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038532\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12797|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=arginine-drug-information\" class=\"drug drug_general\">Arginine: Drug information</a></li><li><a href=\"topic.htm?path=arginine-patient-drug-information\" class=\"drug drug_patient\">Arginine: Patient drug information</a></li></ul></div></div>","javascript":null}